• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

Abbvie Discontinues Manufacturing of the Androgel 1% Pump

Quote












Probably a good thing. It became an unnecessary option with the evolution to 1.62% version. Despite the name, 1.62% more convenient than previous iteration for all parties - most importantly, the patient.
 








absorption rate, titration differential, less shelf space required both in pharmacy and in medicine cabinet, packaging costs...but you're right, half the actuations is not too difficult to understand.
 




Hate to state the obvious but lets look at this from a big picture perspective. Obviously they are preparing for generic 1% due out any day now. That will not only displace Andro 1% current trx and nrx volume but will quickly knock 1.62 to the curb for most current and new scripts as well.

Beginning of the end for Androgel. Generics rule the US and are more in the drivers seat then ever. Goood luck selling those lame "advantages" of 1.62 to patients, docs, Ocare, Medicare and insurance companies.
 












Top Bottom
Back
Quote